Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Hitgen, Inc.

Sichuan Kelun-Biotech Biopharmaceuticals Co., Ltd.

Hongmei Song

Jingyi Wang

Lichun Wang

Hong Zeng

Qiang Tian

Jiaqiang Cai

Tongtong Xue

Shuai Song

Jing Wang

Liang Xiao

Yao Liu

Guoqing Zhong

Donghai Su

Hanwen Deng

Zujian Tang

Rongrong Long

Haitao Huang

Mingliang Zhao

Wei Zhong

Dong Long

Wei Qi

Liping Liu

Xiaofan Duan

Qijun Ye

Yan Feng

Ao Wang

Jun Zhu

Zhiwen Deng

Zejin You

Yinong Xie

Yuting Tan

Xin Zhou

Gang Chen

Zhenwei Miao

Hong Zhang

Tong Zhu

Ying Wang

Dengnian Liu

Jin Li

Qiang Zhang

Jinqiao Wan

Dengfeng Dou

Jinming Liu

Yan Zhang

Yongyong Wu

Jingchao Feng

Xiao Hu

Xing Wang

Ping Liu

Yan Qing

Xiaoxi Yuan

Nan Yu

Hua Deng

Dylan Dalun Deng

Yun Ren

Yongjia Hao

Xi Zhao

Qifeng Shi

Qiuyan Yang

Li Yin

Benyanzi Yang

Yitao Zhang

Xiaohu Ge

Lei Wu

Long Yang

Ruibin Hu

Daibiao Xiao

Xiaoda Niu

A compound represented by formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a polymorph, a solvate, an N-oxide, an isotope labeled compound, a metabolite or a prodrug thereof, a pharmaceutical composition and a pill container comprising same, a preparation method therefor, and the use thereof in the preparation of drugs for preventing or treating STING-mediated related diseases.

Benzothiophene compound, preparation method therefor and use thereof

Disclosed in the present invention is the use of an anti-HER2 antibody-drug conjugate in cancer treatment. Further provided in the present invention is the use of a pharmaceutically acceptable salt, stereoisomer, or metabolite thereof, or a solvate of each of the foregoing in the manufacture of a medicament for the prophylaxis and/or treatment of a cancer insensitive or irresponsive to a treatment with a HER2-targeting agent.

Use of anti-HER2 antibody-drug conjugate in cancer treatment

Provided is a preparation method of an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing,

Anti-ErbB2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof

A pharmaceutical composition comprising a 4'-thionucleoside phosphamide derivative or a pharmaceutically acceptable salt, ester, hydrate, solvate, and isomer thereof, any crystalline form thereof or racemate, metabolite, or a combination of a mixture thereof with other drugs, and a method and use thereof for disease treatment and/or prevention.

Pharmaceutical composition for tumor treatment or prevention, method, and use thereof

Provided is a method for modifying a chimeric antigen receptor-modified T cell (CAR-T cell). The method comprises expressing an SCFV-CDS TM-4-1BB-CD3&#x3b6; molecule in a T cell. The CAR-T cell prepared using the method can specifically recognize and bind to a tumor cell with elevated expression of a ROBO1 protein, and can be used to prevent and treat a corresponding tumor-related disease.

Cytotoxin and conjugate, uses of same and preparation method therefor

The present invention relates to a method for prophylactically treating or treating a viral disease, comprising administering to a subject in need thereof a dihydropyrimidine compound, and the viral diseases include, but are not limited to, Hepatitis A, Hepatitis B, Hepatitis C, influenza, herpes and acquired immunodeficiency syndrome (AIDS).

Dihydropyrimidine compound and preparation method and use thereof

The invention relates to a polyamide compound and a use thereof. Specifically, the invention relates to a type of polyamide compound (which preferably comprise one or more amide bonds formed by condensation of same or different L-amino acids or D-amino acids), or stereoisomers, crystalline polymorphs, solvates, metabolites, prodrugs or pharmaceutically acceptable salts or esters thereof, or pharmaceutical compositions thereof, as well as a method for preparing the polyamide compound and a use thereof in the prevention or treatment of diseases associated with &#x3ba;-opioid receptor. The polyamide compound of the invention has excellent &#x3ba;-opioid receptor agonistic activity and hydrophilicity, thus having a lesser ability of penetrating the blood-brain barrier and a lower capacity for entering the brain. The compound of the invention has higher selectivity for a &#x3ba;-opioid receptor, lower addictiveness, improved pharmacokinetic properties, and improved safety (lower toxicity and/or fewer side effects), good patient compliance, and/or lesser propensity for developing tolerance, among other excellent medicinal properties.

Polyamide compound and use thereof

The present invention relates to an azetidine derivative for use as a Janus kinase (JAK) inhibitor, a drug composition comprising same, a preparation method therefor, and a use thereof in the treatment of JAK-related diseases comprising, for example, inflammatory diseases, autoimmune diseases, and cancers.

Azetidine derivative, preparation method therefor, and use thereof

Provided in the present invention are a compound of Formula (I), a pharmaceutical composition comprising the same, a method for preparing the same, and use thereof as a NS5B polymerase inhibitor, a DNA polymerase inhibitor or a reverse transcriptase inhibitor for the prevention or treatment of viral diseases or cancers.

Nucleoside phosphate compound and preparation method and use thereof

The present invention relates to a dihydropyrimidine compound having an antiviral activity, a pharmaceutical composition comprising same, a preparation method therefor and the uses thereof in the prevention or treatment of viral diseases including, but not limited to, Hepatitis A, Hepatitis B, Hepatitis C, influenza, herpes and acquired immunodeficiency syndrome (AIDS).

The present invention discloses a method for capturing drug targets, comprising the following steps of: (1) preparing row materials, i.e., compounds and DNA or RNA or one party of other specific affinity materials; (2) linking: covalently linking the compounds to the DNA or RNA or the one party of other specific affinity materials, to obtain labeled compounds; (3) transferring: transferring the labeled compounds obtained in the step (2) into cells by a specific gene transfer method; (4) capturing targets: disrupting the cells in the step (3), and then capturing the DNA or RNA in the step (1) by immobilized complementary DNA or RNA, or capturing the one party of affinity materials in the step (1) by the other party of immobilized specific affinity materials, thus to enrich the targets through the covalently linked labeled compounds and the affinity of the targets; (5) identifying targets: dissociating the enriched targets from a stationary phase, deploying the targets by a gel electrophoresis method or by an equivalent separation method, and comparing differential proteins by proteomics thus to identify the potential targets; and (6) determining targets: expressing or purchasing the targets identified in the step (5) by priority, and comparing by interaction of the compounds with those targets one by one to determine the targets for the compounds. By the method of the present invention, compounds with low membrane permeability may be transferred into cells to be bound with the targets in the cells, to realize the target identification closer to the real physiological environment and thus provide more conclusive evidences for the acting mechanism of the compounds to diseases. Additionally, the method for capturing drug targets of the present invention is novel, easy, efficient, and low in cost, and has good application prospects.

Drug target capturing method

Growing community of inventors

Chengdu, China

Hongmei Song